Gonzalez-Perez, David
Das, Satyajit
Antfolk, Daniel
Ahsan, Hadia S.
Medina, Elliot
Dundes, Carolyn E.
Jokhai, Rayyan T.
Egan, Emily D.
Blacklow, Stephen C. http://orcid.org/0000-0002-6904-1981
Loh, Kyle M.
Rodriguez, Paulo C. http://orcid.org/0000-0001-7480-6566
Luca, Vincent C. http://orcid.org/0000-0001-9427-5520
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM133482, R35GM133482)
Rita Allen Foundation
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Sigrid Juselius Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA220340, R01CA184185, R01CA233512, R01CA262121)
Florida Department of Health grant 20B04
Stanford Maternal and Child Health Research Institute
Article History
Received: 7 March 2022
Accepted: 14 July 2022
First Online: 1 September 2022
Competing interests
: V.C.L., P.C.R. and D.G.P., have filed provisional patents describing the engineering and applications of Delta<sup>MAX</sup> (application numbers PCT/US2020/041765 and PCT/US2020/030977). V.C.L. is a consultant on an unrelated project for Cellestia Biotech. S.C.B. is on the SAB and receives funding from ERASCA, Inc. for an unrelated project, and is a consultant on unrelated projects for Scorpion Therapeutics, Odyssey Therapeutics, Ayala Pharmaceuticals, MPM Capital and Droia Ventures.